anti-CD3/anti-CEA bispecific T-cell engager (Roche)

N/A

Report date: 2026/03/19 16:57:15

Base Information

Drug Nameanti-CD3/anti-CEA bispecific T-cell engager (Roche)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulatorsT cell surface glycoprotein CD3 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5T cell surface glycoprotein CD3

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRoche Holding Ltd

China Registration ClassN/A

Develop Information

Active CompaniesRoche Holding Ltd

Inactive CompaniesN/A

Active IndicationsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A